



6<sup>th</sup> World Congress on

# Targeting Microbiota

## Towards Clinical Revolution

October 28-30, 2018 - Porto, Portugal

### Congress Sessions:

- Microbiota 2018: recent advances & challenges
- Recent analysis, methods, bioinformatics & interpretations
- Strategic role of metabolites and mediators on the microbiota-host cross-talk
- Strategies to manipulate microbiota & medicine of tomorrow

### Microbiota 2018 Speakers



**Psycho neuro immunology and gut microbes**

**Paul Forsythe**  
McMaster University, Canada



**Targeted gut microbiota and short chain fatty acid profile among term and preterm infants**

**Jan Mazela**  
Poznan University of Medical Sciences, Poland



**Honor thy lodgers? Interactions between the built environment microbiome and the human microbiome**

**Markus Egelt**  
Furtwangen University, Germany




**Phage therapy strategy to modulate the child stunting microbiota**

**Mohammadali Khan Mirzaei**  
McGill University, Canada



**Crosstalk between gut microbiota, innate immune cells and endocrine cells in the pancreas regulates autoimmune diabetes**

**Julien Diana**  
Inserm, France



**Recent advances on the relation between the microbiome-gut-brain axis and the neurodegenerative diseases**

**Maria Cecilia Giron**  
University of Padova, Italy



**Sepsis and Microbiota: Obstacles, Recent Advances and strategies**

**Natalia Beloborodova**  
Negovsky Research Institute, Russia



**Individual Differences in the Microbiome and Metabolome During Circadian Misalignment and Sleep Restriction: Associations with the Ability to Maintain Wakefulness**

**Kenneth P. Wright**  
University of Colorado Boulder, USA



**Exploring the role of gut dysbiosis in neuroinflammation and hypertension**

**David Durgan**  
Baylor College of Medicine, USA



**Impact of antibiotic treatment on the human microbiota - a review of the clinical implications**

**Maria Vehreschild**  
University Hospital of Cologne, Germany



**Role of microbes in stem cells transplantation related complication**

**Ernst Holler**  
University Hospital Regensburg, Germany



**MAIT cells (Mucosal-Associated Invariant T cells) in liver disease and antibacterial response**

**Antonio Riva**  
Institute of Hepatology London, United Kingdom



**The effect of gut bacterial metabolites on cardiovascular risk**

**Marcin Ufnal**  
Medical University of Warsaw, Poland



**Using germfree animal models to prove the role of the gut microbiota in liver diseases**

**Philippe Gérard**  
Inra, France



**Link between microbiota & visceral pain: role of bioactive lipids**

**Cenac Nicolas**  
Inserm, France